FLASH NEWS LIVE

Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data

Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data

Alto Neuroscience shares fell 3.1% on Thursday, a day after the company said topline data from its Phase 2 proof-of-concept clinical trial evaluating ALTO-101 was not statistically significant on...

Read Full Article →

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.